Literature DB >> 30277293

Lung cancer in Spanish women: The WORLD07 project.

Pilar Garrido1, Nuria Viñolas2, Dolores Isla3, Mariano Provencio4, Margarita Majem5, Angel Artal6, Enric Carcereny7, Rosario Garcia Campelo8, Pilar Lianes9, Ramon De La Peñas10, Enriqueta Felip11.   

Abstract

The WORLD07 study was a female-specific database, to prospectively characterise the clinical, histological, molecular and treatment-related features in Spanish women with lung cancer. Data were collected from patients' medical records and patient interviews from October 2007 to December 2012. A total of 2,060 women were analysed: median age, 61.3 years; white, 98.6%; postmenopausal, 80.2%; and no smokers, 55% including never smokers and ex-smokers. A family history of cancer was found in 42.5% of patients, 12.0% of patients had had a previous history of cancer (breast cancer, 39.7%). Most patients (85.8%) were diagnosed of non-small-cell lung cancer (NSCLC), most commonly reported with adenocarcinoma (71.4%), which was stage IV at diagnosis in 57.6%. Median overall survival (OS) for the entire population was 24.0 months, with a 1- and 2-year survival rate of 70.7% and 50.0% respectively. Median OS in patients with small-cell lung cancer was 18.8 months versus 25.0 months in patients with NSCLC (p = 0.011). Lung cancer appears to be a biologically different disease in women. By collecting prospective information about characteristics of women with lung cancer attending university hospitals in Spain, we hope to highlight the need to develop strategies based on gender differences and influence future healthcare policy.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  lung cancer; prognostic factors; tobacco; women; women’s health

Mesh:

Substances:

Year:  2018        PMID: 30277293     DOI: 10.1111/ecc.12941

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  1 in total

1.  The cost of lost productivity due to premature lung cancer-related mortality: results from Spain over a 10-year period.

Authors:  Josep Darbà; Alicia Marsà
Journal:  BMC Cancer       Date:  2019-10-23       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.